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Preface
An agreement har been signed by the Dutch Expert Committee for
Occupational Standards (DECOS) of the Dutch Health Council and the Nordic
Expert Group for Criteria Documentation of Health Risks from Chemicals (NEG).
The purpose of the agreement is to write joint scientific criteria documents which
could be used by the national regulatory authorities both in the Netherlands and in
the Nordic Countries.
The evaluation of health effcts of Glutaraldehyde is a product of this agreement.
The draft document was written by Drs Brita Beije and Per Lundberg at the
Department of Toxicology and Chemistry, National Institute for Working Life,
Solna, Sweden. The document has been reviewed by the Dutch Expert Committee
as well as by the Nordic Expert Group.
V.J. Feron Per Lundberg
Chairman Chairman
DECOS NEG
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11. Introduction
The first report of the synthesis of glutaraldehyde appeared in 1908, but it was not
until the early 1960s that the commercial use of glutaraldehyde, as a tanning agent,
was recognised. This was followed by many other uses, such as a fixative in
electron microscopy, a cross-linking agent for proteins and enzymes, as a
disinfectant for instruments in the health care system. When the use of
formaldehyde was questioned in the early 1970s due to potential health risks, the
use of glutaraldehyde was further increased.
2. Chemical identification
Common name: glutaraldehyde
CAS number: 111-30-8
Synonyms: glutaral, glutardialdehyde,
glutaric dialdehyde, 1,5-pentanedial,
1,5-pentanedione, 1,3-diformylpropane,
sonacide
Molecular formula: C5H8O2
Structural formula: CHO-(CH2)3-CHO
Molecular weight: 100.13
3. Physical and chemical properties
Freezing point -14 oC
Boiling point 188 oC
Density (specific gravity): 0.72
(water =1)
Vapour density: 3.4 (air=1)
Vapour pressure: 0.00016 kPa (2 % solution)
(at 20° C) 0.002 kPa (50 % solution)
2Saturation vapour conc: 6.6 mg/m3 (1.6 ppm) (20 % solution)
82 mg/m3 (20 ppm) (50 % solution)
Partition coefficient log Po/w = 0.01
n-octanol/water
pH value: 3-4 (in solutions)
7.5-8 (activated solutions)
Conversion factors: 1 mg/m3 = 0.25 ppm
(at 20° C) 1 ppm = 4.0 mg/m3
Glutaraldehyde is a colourless, oily liquid, with a pungent, aldehyde odour. The odour
threshold value is 0.04 ppm (1, 7). Glutaraldehyde is soluble in water and ethanol in all
proportions. Glutaraldehyde is also soluble in benzene, ether, and similar organic
solvents. Glutaraldehyde is corrosive. Glutaraldehyde can react violently with strong
oxidisers, heat is produced in the presence of strong alkalies or strong acids, and
glutaraldehyde may initiate polymerisation in the presence of amines. Glutaraldehyde
does not burn and there is no danger of explosion or auto ignition. The combustion and
thermal products are carbon monoxide and carbon.
4. Occurrence, production and use
Glutaraldehyde is commonly available as a clear, colourless aqueous solution.
Usually available as 1%, 2%, 25% or 50% solutions of glutaraldehyde liquid in
water, but other formulations are also available. Commercial solutions may contain
other chemicals which may affect the overall toxicity and characteristics of the
solution.
Alkaline solutions of glutaraldehyde (pH 7.5-8.5) is a highly effective micro-
biocidal agent and widely used in the cold sterilisation of medical, surgical and
dental equipment (70). Glutaraldehyde is used as a slimicide in the paper industry
(30).
Glutaraldehyde is widely used as a disinfectant and sterilising agent (usually as a
2% solution) in medical and dental settings, in embalming (25% solution), as an
intermediate and fixative for tissue fixing in electron microscopy (20, 50, and 90%
solutions) and in X-ray films, in the tanning industry, in the manufacture of
adhesives and sealants, as a biocide in water cooling towers, as a cross-linking
agent, and in microcapsules containing flavouring agents.
Glutaraldehyde is used as an agent to cross-link collagen strands, thereby
strengthening tissues for use in bioprosthetic devices (48, 56).
Glutaraldehyde has been used in systemic chemotherapy to treat drug-loaded
erythrocytes in order to produce specific targeting of the red blood cells to the liver
in rodents and other animal species (108), as well as in one man (97).
Glutaraldehyde treatment was able to reduce the release of the drug, and the efflux
3rate from the treated cells was dependent on the glutaraldehyde concentration. The
lowest rate was detected at 0.3% glutaraldehyde.
Glutaraldehyde has been used as a therapeutic agent for topical treatment of
hyperhidrosis (excessive sweating), for topical treatment of warts in children, for
topical treatment of onychomycosis (fungal nail infection), for friction blister
prevention in soldiers, athletes and ballet dancers.
5. Occupational exposure
In six hospitals in the Southeast of England, 77 samples were collected at 14
locations. Of these samples, 39 were collected with personal sampling devices.
Sampling periods were from 4 to 26 minutes, and the exposure concentrations
measured were between 0.003 and 0.17 mg/m3. The highest exposure during the
survey was 0.17 mg/m3, which was found during the cleaning of suction bottles
with Cidex (trade name for a glutaraldehyde solution). The lowest exposure was
0.003 to 0.006 mg/m3, which was recorded for those working with x ray
processing chemicals (53).
Measurements of glutaraldehyde have been performed in Danish hospitals,
different departments. Both personal sampling and stationary sampling was used.
The highest air concentration of glutaraldehyde was found in a Surgical Department,
where 0.250 to 0.500 mg/m3 were found (80).
In short-time measurements during manual cold sterilisation work with a 2 %
solution of glutaraldehyde the concentration was low in all samples. The geometric
mean of 16 glutaraldehyde measurements was 0.05 mg/m3. The highest value, 0.57
mg/m3, was measured during the cold sterilisation of a gastroscope. During
automatic cold sterilisation the glutaraldehyde exposure levels were from 0.01 to
0.18 mg/m3. Personal sampling was used in this study (70).
When glutaraldehyde was decanted into a bowl, an endoscope disinfected and the
used solution disposed by pouring into a sluice the air concentration was monitored
to be 0.68 mg/m3 (14). In another study of endoscopy suites a short-term level of
0.16 mg/m3 was measured (39). In both these studies personal sampling was used.
Cleaning procedures in operating theatres were performed with disinfectants
containing both formaldehyde and glutaraldehyde. Personal measurements revealed
peak concentrations of glutaraldehyde up to 0.03 ppm. The time-weighted average
during an 8-h shift the mean value of glutaraldehyde was 0.01 ppm (10).
In the atmosphere above a commercial sterilizing product at concentrations about
2 % glutaraldehyde it is suggested that air concentrations of up to 2 ppm (8 mg/m3)
glutaraldehyde can be formed (81).
The air levels of glutaraldehyde in X-ray darkrooms has been measured by
personal and stationary samplers to be 0.16 mg/m3 (short term, median level)
during decantation in endoscopy suites and <0.009 mg/m3 in darkrooms (39).
46. Sampling and analysis of substance at work place
There is a fully validated method (73) involving the collection on two glass fibre
membrane filters, each coated with 2,4-dinitro phenyl hydrazine and phosphoric
acid. Acetonitrile is used for desorption. Analysis is done by high pressure liquid
chromatography (HPLC) using a UV detector. The detection limit is 18 m g/m3 (4.4
ppb) for a sampling volume of 15 L at a sampling rate of 1 L/min. Later (23), a
detection limit of about 3 ppb for a 2 L sample has been reported for the OSHA-
method.
In another method XAD-2 sorbent tubes coated with 2,4-dinitrophenylhydrazine
(DNPH) are used for collection and the hydrazones formed are desorbed with
toluene or diethylether. Analysis is performed with gas chromatography using a
flame ionisation detector. In a later method from NIOSH, the sampling is performed
on a silica gel coated with 2,4-dinitrophenylhydrazine-HCl. After extraction with
acetonitrile the glutaraldehyde dinitrophenylhydrazone is detected by HPLC-UV at
365 nm. The working range for a 20 L sample is 0.01 to 0.3 ppm (0.04 to
1.2 mg/m3) (3, 69).
Quantitative determination of glutaraldehyde, formaldehyde and acrolein in air
samples has been described. Known volumes of air are drawn through sampling
tubes, containing Amberlite XAD-2, coated with DNPH as adsorption material. The
hydrazones formed are desorbed using acetonitrile as eluent. The separation of the
three compounds is performed on a RP (Reversed Phase) C-18 column. For
detection at l  = 365 nm an UV spectrophotometer is used. The detection limits,
based on a 3 l air sample and an injection volume of 15 m l, were estimated to
0.02 mg/m3 (glutaraldehyde), 0.04 mg/m3 (formaldehyde) and 0.015 mg/m3
(acrolein) (80).
In a Norwegian method (96) samples were collected on a Sep-Pak DNPH-Silica
cartridges followed by elution with acetonitrile and analysis by HPLC. The
recovery was 87 – 5 %.
7. Toxicokinetics
7.1. Uptake and distribution
The uptake of glutaraldehyde has been investigated in a variety of biological
systems.
In an in vitro  study in skin samples of F344 rats, CD-1 mice, rabbits, guinea
pigs and humans less than 1 % of the applied glutaraldehyde penetrated the skin
(92). This abstract only states two dose levels but not the concentrations.
A flow-through skin penetration chamber has been used to determine the in vitro
skin penetration over a 6 h exposure period of 0.75 and 7.5 % [1,5-14C]-
glutaraldehyde on excised skin from Fischer 344 rats, CD-1 mice, Hartley guinea
pigs, New Zealand white rabbits, and human beings. Total recovery from all
species ranged from 75-92 % for both concentrations. Overall, <0.5 % of 0.75 %
5glutaraldehyde and <0.7 % of the 7.5 % solution was absorbed through the skin.
For human beings, approximately 0.2 % of the applied radioactivity penetrated the
skin for both doses tested, largely due to binding to the skin (36).
Percutaneous penetration of glutaraldehyde has been studied using isolated
stratum corneum and epidermis prepared from whole human skin obtained at
autopsy (79). Isolated stratum corneum from chest and abdomen as well as epi-
dermis from abdomen were treated in vitro with 450 m l of a 10 % aqueous glutaral-
dehyde solution. The percutaneous penetration was 12 % of applied dose for
stratum corneum from chest and 13.8 and 3.3 % of applied dose for stratum
corneum from abdomen of two different individuals. The percutaneous penetration
of glutaraldehyde through abdominal epidermis from three different individuals was
3.3, 4.4, and 2.8 % of applied dose.
7.2. Biotransformation
Extensive metabolism of glutaraldehyde to CO2 has been described in in vivo and in
vitro studies using 14C-glutaraldehyde as a tracer (51, 66, 71, 74). Although direct
identification of the metabolites has not been accomplished, the probable metabolic
pathway involves a series of oxidation, decarboxylation and hydroxylation reactions
(7, 71). The initial step is probably oxidation of glutaraldehyde to glutaric
semialdehyde, followed by oxidation to glutaric acid, which can undergo further
metabolism by synthesis of a Coenzyme A thioester. The glutaryl CoA produced is
then oxidised by glutaryl CoA dehydrogenase to give glutaconyl CoA, which is
then decarboxylated to crotonyl CoA (9, 71). The crotonyl CoA is then converted
by enoyl CoA hydratase to b -hydroxybutyryl CoA, which can be subsequently
used for synthesis of acetoacetate or be degraded to acetate and then to CO2.
Evidence that glutaraldehyde undergoes oxidation derives from in vitro studies in
rat liver mitochondria in which an increase in oxygen consumption was measured.
The oxidation of glutaraldehyde involves the electron transport system and results in
reduction of NAD+ and consumption of two atoms of oxygen per molecule of
glutaraldehyde. Glutaraldehyde was oxidised extensively to CO2 in rat tissue slices,
with the greatest activity occurring in the kidney and then the liver. The activity was
localised in the mitochondrial fraction of the kidney (51, 71, 74).
Material balance studies and pharmacokinetic studies were conducted with groups
of Fischer 344 rats and New Zealand white rabbits using both intravenous (i.v.)
and epicutaneous dosing. The animals received an i.v. dose of either 0.075 or
0.75 % glutaraldehyde in the tail vein or ear vein, respectively. Concentrations of
0.75 and 7.5 % glutaraldehyde were applied to the skin under a 24 h occlusive
period. After i.v. administration up to 80 % of the dose was recovered as 14CO2.
The calculated dermally absorbed doses ranged from 4.1-8.7 % in the rat and
33-53 % in the rabbit. The mean concentration of radiochemical in animals
receiving epicutaneous [14C]glutaraldehyde were 100-1000 times less than those
following i.v. injection of corresponding concentrations of glutaraldehyde (62).
The systemic distribution of glutaraldehyde has been studied in male Sprague-
Dawley rats (78) being exposed to 14C-glutaraldehyde, which was either deposited
6in the maxillary left first molar, or infused into the jugular vein. A 0.4 m l aliquot of
4 % glutaraldehyde was administered in the pulp chamber and the intravenously
administered dose was 10, 15, 20, 25, 30 , or 50 % of the amount deposited in the
pulp chamber. The systemic distribution was estimated to 25 % of the applied dose
in the maxillary molar, which amounts to a body load of 40 nanomoles of glutaral-
dehyde. After 45 min the tissue/fluid ratio (g tissue/ ml serum) of isotopic activity
was 3 for the liver and 4.5 for the kidney. Similar ratios were also found for the
metabolic clearance studies. Glutaraldehyde was rapidly metabolised to carbon
dioxide (77, 78).
7.3. Tissue clearance and elimination
Following intravenous administration of 0.075 % and 0.75 % solutions of 14C-
glutaraldehyde to F344 rats and New Zealand white rabbits (0.2 ml for rats and
2.5 ml for rabbits), the majority of the radiolabel was excreted as CO2, with
approximately 80 % being exhaled in the first 4 hours. Urinary excretion of
radiolabel ranged from 8 % to 12 % in the rat and 15 % to 28 % in the rabbit.
Excretion of CO2 as a percentage of total dose was less at the higher dose,
particularly in the rabbit (5, 71).
In the studies by Ranley et al (77, 78) described above the clearance of 14C-
glutaraldehyde from liver, kidney, serum, and muscle was followed for 7 days after
the exposure. After 1 hr, 81 % of the initial tissue load remained in the liver, 42 %
in the kidney, 24 % in serum, and 67 % in muscle. After 7 days, the radioactivity
remaining in the liver was 8 %, in the kidney 7 %, in serum 1 %, and in muscle
0.7 %. The 14C from glutaraldehyde was exhaled as carbon dioxide or excreted in
the urine (metabolite not given). At the end of 24 hr, 42 % of the administered
radioactivity was eliminated and 90 % was cleared from body tissues in 3 days.
After 6 days both routes were still being used for elimination (77, 78).
8. Methods of biological monitoring
Today, there is no suitable method described for biological monitoring of
glutaraldehyde.
9. Mechanisms of toxicity
Glutaraldehyde can react and cross-link proteins. It can react with the a -amino
groups of amino acids, the N-terminal amino groups of peptides and the sulfhydryl
group of cysteine. The predominant site of reaction in proteins is the e -amino group
of lysine, although reactions may also occur with tyrosine, histidine and sulfhydryl
residues (7, 42, 71, 75).
Products are formed on reaction of glutaraldehyde with deoxyadenosine,
deoxyguanosine and deoxycytidine but not with deoxythymidine. The adducts
7formed with deoxyadenosine are unstable but those formed on reaction with
deoxyguanosine are relatively stable (7. 47. 71).
In the study by St. Clair and coworkers (87) it was shown that glutaraldehyde
instilled in the nose of rats, induced lesions (inflammation, epithelial degeneration,
respiratory epithelial hypertrophy and squamous metaplasia) that resembled, both in
nature and in severity, the changes observed after acute inhalation exposure of rats
to carcinogenic concentrations of formaldehyde gas (15, 64). Glutaraldehyde
induces regenerative cell proliferation (87) and is about an order of magnitude more
toxic to the nasal epithelium than formaldehyde (107).
10. Effects in animals and in vitro studies
10.1. Irritation and sensitisation
Irritation
Glutaraldehyde solutions may cause mild to severe irritation to the skin, depending
on the concentration of the solution and the duration of exposure/contact. Dermal
exposure to 25% glutaraldehyde solution or more caused necrosis in rabbits (5, 83).
Glutaraldehyde vapour is irritating to the eye at an air concentration of 0.2 ppm
(0.8 mg/m3). At higher concentrations serious, irreversible injury may occur (7, 8,
49).
An alkaline 2 % glutaraldehyde solution was applied to the intact and abraded
skin of rabbits for 24 h and irritation was scored at 24 and 48 h. Glutaraldehyde
was a moderate skin irritant; the primary irritation index was 2.125 (maximum
possible score 8.0) (63).
A 0.5 ml dose of a 2 % aqueous alkaline solution of glutaraldehyde was applied
for 6 weeks to the clipped dorsal skin of 20 albino rabbits. The solution was spread
with a brush and allowed to dry. The skin was examined daily. After the first
application the skin and hair were stained faint yellow. The stain became more
intense and turned golden brown during the 6 weeks, and it persisted for up to
35 days after the last application. Erythema was mild and a mild rash was observed
following the first few applications. A severe erythematous reaction with edema
followed by necrosis and scarring was observed when 24 % glutaraldehyde was
applied to the skin of rabbits (90).
A single drop of a 2 % acid glutaraldehyde solution was placed in one conjunc-
tival sac of each of two Dutch belted rabbits and the eyes were observed periodically
for 72 h whereafter the animals were killed. Edema and swelling of the conjunctiva
were observed 6 h after glutaraldehyde administration. Swelling and exudate was
moderate at 18 h and the cornea was cloudy at 24 h. At 72 h the cornea remained
cloudy and the conjunctiva was red and inflamed. The 2 % acid glutaraldehyde
solution, thus, produced severe and extensive conjunctival injury (59).
In another study a 0.1 ml volume of an alkaline 2 % glutaraldehyde solution was
placed in one conjuctival sac of the eye of each of 12 rabbits. After 30 seconds the
8eyes of 3 rabbits were rinsed. Severe corneal opacity and irritation of the iris and
conjunctiva were observed in unrinsed eyes after 7 days. Irritation of the conjunc-
tiva, which was similar in rinsed eyes, lasted 7 days. The authors concluded that the
alkaline 2 % glutaraldehyde solution was a severe ocular irritant (63).
When 0.1 ml volume of an alkaline 2 % glutaraldehyde solution was instilled into
the conjunctival sac of one eye of five albino rabbits, inflammation lacrimation and
edema were observed. A severe eye irritation was caused by this glutaraldehyde
solution in rabbits (90).
In an alternative to the Draize rabbit eye test, glutaraldehyde was cytotoxic to
human corneal endothelial cell cultures (28).
In a respiratory irritation study, groups of four ND4 Swiss Webster mice were
exposed to seven different glutaraldehyde vapour concentrations in the range of 1.6
to 36.7 ppm (6.4 to 146.8 mg/m3) while the respiratory rate was measured.
Concentration related decreases in the respiratory rate were measured with a
maximum at 3 to 20 minutes. The 50 % decrease in respiratory rate, RD50, was
calculated to be 13.9 ppm (55.6 mg/m3) (103).
Sensitization
Female albino Hartley strain guinea pigs were sensitised with 0.3, 1.0, and 3.0 %
glutaraldehyde and challenged with 10 % glutaraldehyde (89). The guinea pigs
received 100 m l by direct dermal application for 14 consecutive days, followed by a
rest period for 7 or 14 days. The primary irritancy response, determined by visual
scoring or radioisotopic assay, indicated a minimal irritation concentration of 10 %
glutaraldehyde, and a maximal non-irritating concentration of 3 % glutaraldehyde.
The irritancy index was 3 for 0 % glutaraldehyde, almost 5 for 1.0 % glutaral-
dehyde (p<0.05 vs 0 %), and about 7 for 10 % glutaraldehyde (p<0.01 vs 0 %).
Furthermore, contact hypersensitivity to glutaraldehyde followed a dose-dependent
response. The hypersensitivity index was <0.5 for 0 % glutaraldehyde, about 1 for
1.0 % glutaraldehyde (p<0.05 vs 0 %), and about 2.6 for 3.0 % glutaraldehyde
(p<0.01 vs 0 %). (The irritancy and hypersensitivity indices are calculated for each
animal. The mean of the left (treated) to right (untreated) ratios of the biopsis of the
vehicle group animals were calculated and this non-specific contribution was
subtracted from the left to right ratio of every other animal. The resulting value was
the index for the animal.)
In the same study (89) female B6C3F1 mice were sensitised with 0.3, 1.0, and
3.0 % glutaraldehyde and challenged with 10 % glutaraldehyde. The vehicle used
was one part olive oil and four parts acetone. The mice  received 20 m l by direct
dermal application for 5 or 14 consecutive days, followed by a rest period for 4 or
7 days. The primary irritancy response, determined by visual scoring or radio-
isotopic assay, indicated a minimal irritation concentration of 10 % glutaraldehyde,
and a maximal non-irritating concentration of 3 % glutaraldehyde. The irritancy
index was almost 2 for 0 % glutaraldehyde, 3 for 1.0 % glutaraldehyde, and about
5.5 for 10 % glutaraldehyde (p<0.01 vs 0 %). Furthermore, contact hyper-
sensitivity to glutaraldehyde followed a dose-dependent response. The hyper-
sensitivity index was about 0.1 for 0 % glutaraldehyde, about 0.6 for 0.3 %
9glutaraldehyde (p<0.01 vs 0 %), and about 2.2 for 1.0 and 3.0 % glutaraldehyde
(p<0.01 vs 0 %).
Glutaraldehyde has been used to validate the mouse ear swelling test. To the
shaved and tape-stripped abdomens of 10 mice 100 m l of 1 % glutaraldehyde was
applied and allowed to dry. This procedure was repeated for 3 consecutive
additional days. After a 7-day nontreatment period 20 m l of 10 % glutaraldehyde
was applied to the left pinna of each animal. The right pinna was treated with 70 %
ethanol, the vehicle. The thickness of both pinna was measured 24 and 48 h later.
Of the animals, 67 % were sensitized to glutaraldehyde and the degree of pinna
swelling was 125 % (37).
It has been suggested (4) that the threshold concentration for glutaraldehyde in
aqueous solution to induce dermal sensitization is in the range of 0.1 to 1.0 %.
Production of IgE antibodies has been studied in mice (BALB/c). Solutions of
glutaraldehyde (water:acetone; 50:50) were applied twice on the shaved flank of the
mice (day 1 and day 7). Serum was collected 14 days after the initial administration
and total serum IgE antibody content was evaluated by an enzyme-linked immuno-
sorbent assay. Glutaraldehyde-treated mice had slightly higher concentration of
serum IgE antibodies than controls. A total of 9.38 mg glutaraldehyde produced a
small but significant elevation in IgE (76).
In a study the radioisotopic incorporation method was compared with the mouse
ear swelling test for its ability to detect weak sensitizers. (In the radioisotopic
incorporation method the infiltration of radiolabeled cells in the ear is evaluated.)
Filter discs treated with 10 % glutaraldehyde (25 m l) were attached to the shaved
and tape-stripped abdomens of 24 Balb/c mice. Glutaraldehyde was applied for
3 additional consecutive days. One day prior to challenge, the discs were removed
and the mice were injected i.p. with 1 mg FUdR (5-fluorodeoxyuridine)/kg bw
followed by 1 m Ci [125I]-iododeoxyuridine 1 h later. On the following day 25 m l of
2 % glutaraldehyde was applied to the left pinna of each animal. The mice were
killed 24-48 h later and the thickness of the pinna was measured. Reactivity to
glutaraldehyde was not detected by the radioisotopic assay, but in the ear swelling
test the mice were slightly responsive (20).
In another study the mouse ear sensitization assay was used to determine the
sensitization potential of glutaraldehyde. The right pinna of 18 female Balb/c mice
were topically treated with 1 % glutaraldehyde on days 0 and 2. A scapular sub-
cutaneous injection of Freund's complete adjuvant was also administered on day 2.
On day 9 the thickness of the pinnae was measured followed by topical application
of 10 % glutaraldehyde. When ear thickness was measured 24 h later there was a
significant increase in thickness (25).
With a modified Magnusson-Kligman test on guinea pigs the sensitising capacity
of glutaraldehyde was tested. A 10 % solution of glutaraldehyde was used on 30
animals. Glutaraldehyde was found to be a potent allergen as 72 % of the animals
were sensitised. Cross-sensitization was shown between glyoxal, formaldehyde
and glutaraldehyde (34).
The respiratory sensitizing potential of glutaraldehyde vapour was studied in male
Hartley guinea pigs. The animals were exposed for one hour per day for five
10
consecutive days to an inducing vapour concentration of 13.9 ppm (55.6 mg/m3).
Challenge exposures to 4.4 ppm (17.6 mg/m3) at 14, 21 and 35 days after the final
induction exposure did not produce any evidence of respiratory sensitisation (103).
10.2. Effects of single exposure
LD50 values reported are presented in Table 1.
No evidence of systemic effects was observed in rats and rabbits that received a
single dermal application of glutaraldehyde as a 2 % aqueous solution (dose
unspecified) (90).
Increasing volumes of a stabilized 2 % glutaraldehyde solution were applied
under an occlusive wrap to the shaved skin of rabbits for 48 h. There were no
deaths when 50 ml glutaraldehyde solution/kg bw, the largest practical achievable
dose, was applied (63).
Intra-arterial injection of glutaraldehyde to mature, non-inbred male rats (0.1 or
0.2 ml/100 g body weight (bw) of a 0.02% solution) gave rise to a temporary
reduction in the amplitude of the EEG, which was more marked after 0.2 ml
glutaraldehyde/100 g bw. The EEG was back to normal after17-22 min. Formal-
dehyde had a synergistic effect. The authors suggested, as one possibility, a
mechanism of inhibition of the EEG linked with competitive blocking of membrane
receptors by products of the aldehyde-mediator interaction. The inhibition of EEG
was fully reversible (52).
Table 1. LD50 values reported after exposure to glutaraldehyde. Data from refs 5, 55,
63, 83, 90, 98.
Species Adm. route Reported LD50 (LC50) value(s)
rat oral 123 mg/kg bw; 1 % water solution
252 mg/kg bw; 2 % saline solution
»  2000 mg/kg bw; 2 % alkaline solution
134-600 mg/kg bw; 25 % solution
dermal 2500 mg/kg bw
i.v. 17.9 mg/kg bw
inhalation 24-40 ppm (96-160 mg/m3)*
mouse oral 100-110 mg/kg bw; 1 % water solution
352 mg/kg bw; 2 % saline solution
i.p. 13.9 mg/kg bw
i.v. 15.4 mg/kg bw
s.c. 1430 mg/kg bw
rabbit dermal 600-2560 mg/kg bw
guinea pig oral 50 mg/kg bw
* [In unpublished reports from the industry the 4 h LC50 for rats is reported to be 280-800 mg/m3.
The animals were exposed head-nose-only to an aerosol of glutaraldehyde.]
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In the study by Ranly et al (78) (described above in chapter 7.2) no significant
glutaraldehyde effects were observed on serum glutamic-oxalacetic transaminases
(SGOT), serum glutamic-pyruvic transaminases (SGPT) or serum creatinine, and
neither on urinary protein and urinary lactate dehydrogenase (LDH). When livers
were examined histologically no evidence of abnormality was found. However, the
uptake of p-aminohippurate was significantly higher in the exposed group and the
clearance of phenosulfonphtalein (PSP) was significantly lower in the group
receiving 2 m moles of glutaraldehyde, but not in those receiving 0.4 m moles of
glutaraldehyde. The clearance of PSP from the blood was used as an endogenous
test of kidney function, but no kidney histopathology was performed.
Male Fisher 344 rats have been exposed to 10, 20 or 40 mM glutaraldehyde by
intra-nasal instillation (87). For the histopathology and cell proliferation studies,
rats received, 72 hours after the glutaraldehyde instillation, an intraperitoneal
injection of 5-bromo-2´-deoxyuridine, which is incorporated by cells in S-phase.
Two hours later the rats were killed and the nasal cavity was prepared for
examination by light microscopy. The lesions scored were; squamous metaplasia,
rhinitis, epithelial erosions, epithelial hyperplasia, and goblet cell hypertrophy. The
distribution of glutaraldehyde induced nasal epithelial lesions corresponded with the
localisation of dyes in the deposition study. At 0 and 10 mM glutaraldehyde, no
lesions were observed. Acute inflammatory changes (neutrophilic infiltrates and
epithelial erosion) as well as extensive regions of respiratory epithelial hyperplasia
and squamous metaplasia were observed after exposure to 20 or 40 mM glutaral-
dehyde. The effects were dose-related. Increased cell proliferation was also
observed after 20 and 40 mM glutaraldehyde.
An alkaline 2 % aqueous glutaraldehyde solution was allowed to evaporate freely
at room temperature in a closed system and rats and mice were exposed for 4 h. No
gross effects were observed. Twelve rats exposed to vapours of 1.5 ml glutaral-
dehyde solution per litre of air were slightly more restless than controls. An initial
weight loss was observed in 5 of the 12 rats. None of the 5 mice exposed to
glutaraldehyde died. Two mice had an initial weight loss. Higher concentrations of
glutaraldehyde produced more signs of respiratory tract irritation (90).
Groups of 10 male NMRI mice were exposed for 24 h to 33 and 133 m g/L
(mg/m3). There were 20 control mice. The lungs, liver and kidneys were evaluated
histopathologically. No remarkable gross changes were observed in the lungs or
kidneys but 6 mice exposed to the high dose had toxic hepatitis, that may have been
reversible (99).
10.3. Effects of short-term exposure
10.3.1. In vitro studies
The cytotoxicity of glutaraldehyde in primary human pulp fibroblast cultures has
been studied by Jeng and coworkers (50). The evaluation of cytotoxicity was based
on the staining of the cells, and cell morphology. The fibroblasts, which were
derived from third molar pulps, were treated with a 2.5 % 14C-(1,5) glutaraldehyde
solution (250 m Ci/ml). The maximum non-toxic concentration in solution was 0.65
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m l/ml, and in agar overlay technique 1.20 m l/ml. In another study fibroblasts (3T3
cells) were incubated for 24 hr with glutaraldehyde. A concentration of 3.0 ppm (in
the medium) inhibited almost completely the growth of the fibroblasts, as measured
by incorporation of 3H-thymidine (84).
Cells from a human embryonic lung (WI-38) fibroblast culture were exposed to
serial dilutions of a 2.5 % glutaraldehyde solution (91). Cytotoxicity was measured
as the inhibition of mitochondrial dehydrogenase activity. Maximum non-toxic
concentration was 0.98 mM (3.91 m l/ml, 4 hr), 1.03 mM (4.11 m l/ml, 8 hr), and
0.85 mM (3.40 m l/ml, 24 hr).
Glutaraldehyde is commonly used to produce intramolecular and intermolecular
cross-links in collagen-based biomaterials. The cytotoxicity of glutaraldehyde-
treated pig dermal collagen (19) has been studied by measuring 3H-thymidine
incorporation in adult human skin fibroblasts, when grown for 1 or 3 days in the
presence of the collagen. The glutaraldehyde concentrations were 0.001-0.05 %.
After 1 day exposure to the lowest glutaraldehyde-concentration, the 3H-thymidine
incorporation was reduced to approximately 60 % at the lowest concentration, to
about 30 % at 0.01 % glutaraldehyde and to about 29 % at the highest glutaral-
dehyde concentration. After 3 days of exposure, 3H-thymidine incorporation was
reduced to approximately 50 % at the lowest concentration, to about 20 % at
0.01 % glutaraldehyde and to about 7 % at the highest glutaraldehyde concentra-
tion. In some other studies of the cytotoxicity of glutaraldehyde, effects were
observed at media concentrations greater than 10-20 ppm (104) and at 3 ppm (84).
The in vitro cytotoxicity of glutaraldehyde (31) on bovine aortic endothelial cells
has been evaluated by proliferation capacity, cellular ATP content, PGI2 release and
cyclic AMP synthesis. Continuous incubation of the cells with 0.1-1.0 m g glutaral-
dehyde/ml caused a statistically significant decrease in cell proliferation. More than
0.5 m g/ml glutaraldehyde led to a statistically significant increase in ATP content. A
concentration dependent increase in PGI2 release and cyclic AMP content was also
observed, and at glutaraldehyde concentration over 0.1 m g glutaraldehyde/ml
induced disproportionate amounts of PGI2 and cyclic AMP, indicating a disturbance
of cell functions.
10.3.2. Animal studies
A 0.5 ml dose of a 2 % alkaline glutaraldehyde solution was applied daily for 6
weeks to the clipped skin of albino rabbits. No evidence of systemic toxicity was
observed (90).
Applications of 2.5, 5.0 and 7.5 % aqueous solutions of glutaraldehyde were
ggiven under occlusion to Fischer 344 rats at doses equivalent to 50, 100 and
150 mg/kg bw during 6 h/day for 20 application over a period of 26 days. No
treatment-related mortalities or clinical signs of systemic toxicity were found. Local
skin irritation, mainly erythema and edema was minimal and present only inter-
mittently during the treatment period (102).
In 2-week inhalation studies, groups of five rats (F344) and five mice (B6C3F1)
of each sex were exposed to vapours of glutaraldehyde by inhalation at concentra-
tions of 0, 0.16, 0.5, 1.6, 5 and 16 ppm (0, 0.64, 2.0, 6.4, 20 and 64 mg/m3) for
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6 hours per day, 5 days per week. All rats and mice exposed to 5 or 16 ppm
glutaraldehyde died before the end of the studies, as did all mice exposed to
1.6 ppm. Rats exposed to 1.6 ppm did not gain weight. Deaths were attributed to
respiratory distress. Lesions noted in the nasal passage and larynx of rats and mice
included necrosis, inflammation and squamous metaplasia. At higher exposure
concentrations similar lesions were present in the trachea of rats and mice and in the
lung and on the tongue of rats. At 0.5 ppm nasal hyperplasia was seen in 3 male
rats and squamous metaplasia in 2 males and one female. One female rat had
necrosis/inflammation in larynx. There were higher incidences of these effects at
higher concentrations. At 1.6 ppm all rats had necrosis in the nasal passages and
squamous metaplasia was seen in 2 male and all female rats. At 5.0 ppm similar
effects were seen in trachea. The NOEL in this study appears to be 0.16 ppm (71).
Male Swiss OF1 mice (107) were exposed for 6 h/day to; a) 0.3   +0.1 ppm,
0.9   +0.2 ppm or 2.6   +0.2 ppm glutaraldehyde for 4 consecutive days; b) 0.3   +0.1
ppm or 1.0   +0.2 ppm glutaraldehyde for 5 consecutive days in the first week and for
4 consecutive days in the second week; c) 0.3   +0.1 ppm or 0.9   +0.2 ppm glutaral-
dehyde for 5 consecutive days in the first 2 weeks and for 4 consecutive days in the
third week. Some mice (4/10) exposed to 2.6 ppm glutaraldehyde were dying on
the third day. As the surviving mice showed signs of severe toxicity (weight
decrease, mouth breathing etc), they were killed after 5 days. The breathing
frequency was used as an index of sensory irritation (Alarie 1973). In the
concentration range 0.7-4.5 ppm glutaraldehyde (15 min oronasal exposure), a
concentration dependent expiratory bradypnea was observed. RD50 (50 % decrease
in respiratory rate) was 2.6 ppm. After 14 days of exposure to 1.0 ppm glutaral-
dehyde, the decrease in body weight was about 20 %. Exposed mice showed
marked excitation by nervously running around, abdominal swelling, rougher hair,
and looking unhealthier. No signs of systemic toxicity were observed in mice
exposed to 0.3 ppm glutaraldehyde. Histopathological lesions were observed in all
mice exposed to 0.3, 1.0, 2.6 ppm. The lesions affected exclusively the respiratory
epithelium covering the septum, the naso- and maxilloturbinates and also to a lesser
extent the lateral wall, but not the olfactive one. The severity of lesions increased
with glutaraldehyde concentration from 0.3 ppm to 1.0 ppm and remained constant
from 1.0 to 2.6 ppm in the surviving mice, but it did not depend on exposure time.
Inhalation of 1.0 ppm glutaraldehyde for 14 days caused a marked increase in
squamous metaplasia, exudate of keratin strates and inflammatory cells, and
necrosis of the respiratory epithelium in the nasal cavities. After 1 and 2 weeks
recovery, the effects remained. However, after two weeks the severity of squamous
metaplasia was somewhat reduced, necrosis was even further reduced and the
increase in keratin exudate was completely reverted. No concentration-related
lesions were observed in the lungs of the exposed mice (107).
Groups of 3 rats were given drinking water containing 0.05, 0.1 or 0.25 %
glutaraldehyde for 11 weeks. The rats were then killed and the nervous system
tissue was examined microscopically. No signs of adverse effects were found (85).
Feigal and Messer (32) have shown that glutaraldehyde used as a pulpotomi agent
penetrates into surrounding tissue in small but measurable amounts.
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10.4. Effects of long-term exposure and carcinogenicity
In 13-week studies, groups of 10 rats (F344) and 10 mice (B6C3F1) of each sex
were exposed to vapours of glutaraldehyde by inhalation at concentrations of 0,
62.5, 125, 250, 500 and 1000 ppb for 6 hours per day, 5 days per week. There
were no exposure-related deaths in rats but all mice exposed to 1000 ppb and two
female mice exposed to 500 ppb died before the end of the study. Body weight
gains were reduced in male rats exposed to 1000 ppb, in female rats exposed to 500
or 1000 ppb, in male mice exposed to 125, 250 or 500 ppb and in female mice
exposed to 250 or 500 ppb. There was no evidence of systemic toxicity in rats or
mice by histopathologic or clinical pathology assessments. Exposure-related lesions
in the respiratory tract were, however, observed and resembled those in the 2-week
studies. A NOAEL for respiratory lesions was decided to be 125 ppb in rats. No
NOAEL was reached in mice as inflammation was found in the anterior nasal
passage at concentrations as low as 62.5 ppb. The inflammation was characterized
by focal accumulation of neutrophils in the nares, particularly in females. The
neutrophilic infiltrate became progrssively more severe and was associated with
increased epithelial cell replication in the anterior nasal passages (71).
From the histopathology of the respiratory tract of the animals in the NTP-study
there is a separate report (41). Treatment-induced lesions, including epithelial
erosions, inflammation, and squamous metaplasia, were confined to the anterior
third of the nose and were present in both sexes and in both rats and mice. No
histopathological evidence of glutaraldehyde-induced responses was observed in the
trachea, central airways, or lungs, while the larynx showed minimal changes.
Neutrophilic infiltration of the squamous epithelium of the nasal vestibule, present
in both rats and mice, became progressively more severe with increasing exposure
time. Lesions induced by glutaraldehyde were more anterior in the nose than those
reported for formaldehyde.
A carcinogenesis study (inhalation) performed for the NTP has not yet been
finalised (72).
[A two-year carcinogenicity study has been performed by industry. The results
are not published but they are referred to by the US Cosmetic Ingredient Review
Expert Panel (17). Fischer rats were given 50, 250, andd 1000 ppm glutaraldehyde
in drinking water. Large granular lymphocytic leukemia (LGLL) was found in
dosed females at necropsy. The incidence of LGLL is high in untreated controls.
The conclusion was: The nature of the response and the factors associated with it,
suggest that this was not a direct chemical carcinogenic effect but resulted from a
modifying influence on determinants normally controlling the expression of this
spontaneously occurring neoplasm.]
10.5. Mutagenicity and genotoxicity
Glutaraldehyde was tested for inductions of mutations in Salmonella typhimurium
in three laboratories. In one laboratory positive results were obtained with strain
TA100 with and without liver S9 from Aroclor 1254-induced male Sprague Dawley
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rats or Syrian hamsters. In the second laboratory no increase in mutations was
observed in TA100 in the absence of S9 or with 10 % Aroclor-induced hamster S9.
A small increase in mutations was noted in TA100 in the presence of 10 % Aroclor-
induced rat S9. In both laboratories negative results were obtained with the strains
TA1535, TA1537 and TA98 with and without S9. The third laboratory reported
positive results in strains TA100, TA102 and TA104 with and without Aroclor-
induced hamster or rat liver S9 (44, 71).
  In a liquid preincubation procedure with the base substitution strain Salmonella
typhimurium TA104, it was shown that glutaraldehyde at its maximum non-toxic
dose (>0.5 m moles) induced 4 150 revertants/m mol glutaraldehyde. The average
spontaneous reversion value of 304 had been subtracted. In the liquid preincubation
procedure the test substance and the bacteria were incubated at 37 oC for 20
minutes. Following incubation histidine and biotine were added, the mixture plated
and revertants recorded after 48 hours. The strain TA104 carries a nonsense
mutation (-TAA-) at the site of reversion that is present in a single copy on the
chromosome (58). In Salmonella typhimurium TA102, which detects oxidative
mutagens, glutaraldehyde (25 m g/plate) induced His+ revertants (389 rever-
tantss/plate, the spontaneously induced 240 revertants/plate subtracted), which was
equal to the number of revertants induced by formaldehyde. The strain TA104
contains A-T base pairs at the site of mutation (54).
The cytotoxic and genotoxic effects of glutaraldehyde have been studied in vitro
in the human TK6 lymphoblast cell line and in primary cultures of rat hepatocytes.
TK6 lymphoblasts were exposed to glutaraldehyde for 2 hours in serum-free GSH-
free media. Cytotoxic effects were observed at concentrations as low as 10 m M with
only 10 % cell survival at 20 m M. Glutaraldehyde-induced DNA-protein cross-
linking increased linearly over the concentration range from 0 to 25 m M. Glutaral-
dehyde induced a marginal increase in unscheduled DNA synthesis in the in vitro
hepatocyte DNA repair assay, but only at the two highest concentrations of 50 and
100 m M, indicating the induction of some excision-repair activity (71, 86).
Glutaraldehyde induced mutations at the TK+/- locus of mouse L5178Y cells at a
concentration of 8 m g/mL in the absence of S9 activation. Glutaraldehyde induced
sister chromatid exchanges (SCEs) in Chinese hamster ovary cells with and without
S9 activation (38, 61, 71).
Glutaraldehyde was tested for its ability to induce sex-linked recessive lethal
mutations in germ cells of male Drosophila melanogaster treated as newly emerged
adult flies by feeding or injection or treated as larvae by feeding. All three tests were
negative. (71, 105, 106).
The genotoxic potential of 50 % aqueous glutaraldehyde was assessed in vivo
using a micronucleus test in mice and a bone marrow chromosomal aberrations test
in rats. Glutaraldehyde was given to male and female Swiss-Webster mice (num-
bers not given) as a single dose by peroral intubation at 80, 160 and 250 mg/kg bw.
Glutaraldehyde did not produce dose-related increases in the frequency of micro-
nucleated polychromatophilic erythrocytes sampled 30, 48 or 72 hour after
treatment. The single doses of glutaraldehyde given by peroral intubation to
Sprague Dawley rats were 25, 60 or 120 mg/kg bw for males and 15, 40 and
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80 mg/kg bw for females. There were no dose-related increases in the frequency of
chromosomal aberrations in rats assessed at 12, 24 or 48 hours after treatment
(100).
In summary, glutaraldehyde was shown to be genotoxic in vitro inducing
mutations in bacterial cells and producing mutations, sister chromatid exchanges
and chromosomal aberrations in mammalian cells. Its mutagenic activity was
independent of S9 activation.
10.6. Reproductive and developmental toxicity
The effects of glutaraldehyde in male reproductive function using the dominant
lethal assay have been studied in male mice, administered a single dose (per os) of
30 or 60 mg glutaraldehyde per kg bw and mated for the next 6 weeks with virgin
females. There were no evidence of reduced fertility and no significant effects on
embryonic/foetal viability (94).
In a subacute toxicity study (98), groups of Sprague-Dawley rats were given
daily doses s.c. of 1, 5, 25 or 125 mg glutaraldehyde/kg bw for 35 days. A control
group received saline. Changes on testes/sperm duct/epididymis, and prostate/
seminal vesicles/Cowpers gland/urethra were seen in male rats in the two highest
dose groups. In female rats, changes in uterus/cervix/vagina were seen at these dose
levels.
In a study CD1-mice were given by gastric intubation 16, 20, 24, 40, 50 or
100 mg glutaraldehyde/kg bw of a product containing 2 % glutaraldehyde on days
6 through 15 of gestation. Nonionic ethoxylates of isomeric linear alcohols
[(CH3)2(CH2)nO(CH2CH2O)12H with 11£ n£ 15] and possibly orthophosphoric acid
were also present. The mice were killed at day 18 of gestation. At daily doses of
40 mg/kg bw six of 35 animals died as did 12 of 48 mice given 50 mg/kg bw and
19 of 35 given 100 mg/kg bw. There was a significant (p<0.05) reduction in
average weight gain during pregnancy. The unborn offspring of dams treated at the
highest dose level were also adversely affected. At the lowest exposure group
(16 mg/kg bw) there was a significant decrease in the average fetal weight. The
group given 100 mg/kg bw produced a significant increase in the average percent
malformed fetuses. Mainly due to the toxic effects on mothers, including deaths, the
authors concluded that the glutaraldehyde-containing product was not teratogenic
toward the CD1-mouse (57).
In another study (29) pregnant rats were given glutaraldehyde by gastric
intubation at a dose of 0, 25, 50 or 100 mg/kg bw on days 6 through 15 of
pregnancy. Maternal toxicity occurred in the 100 mg/kg group as evidenced by a
significant increase in maternal death and a significant decrease in maternal body
weight gain and food consumption. A significantly lowered fetal weight was also
found in the 100 mg/kg group. No significant change induced by glutaraldehyde
was detected in the incidence of postimplantation loss. Morphologic examinations
of fetuses revealed no evidence of teratogenicity of glutaraldehyde. The authors
concluded that glutaraldehyde has no teratogenic effects on rat offspring even at a
dose which induced severe maternal toxicity.
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[Oral doses of 25 and 50 mg/kg of glutaraldehyde given to rats on days 6 to 15 of
gestation were maternally toxic but not fetotoxic as reported in an unpublished
industrial report.]
[In another unpublished study, reported by the Cosmetic Ingredient Review
Expert Panel (17) groups of CD rats were given glutaraldehyde in drinking water;
0, 50, 250 and 1000 ppm for 10 weeks. The rats were then paired within each dose
group. Treated water was administered throughout the mating, gestation and
lactation periods. Groups of F1 rats were administered glutaraldehyde at the same
concentrations as their parents. They were allowed to mate and produce a F2
generation. The investigators concluded that the NOAEL for adult and offspring
toxicity was 50 ppm and 250 ppm glutaraldehyde in drinking water, respectively.
The NOAEL for reproductive effects was > 1000 ppm in drinking water]
10.7. Immunotoxicity
No studies on immunotoxic effects of glutaraldehyde have been found in the
literature. It should be noted, however, that total serum IgE antibody content was
elevated in mice given dermal application of 50 % glutaraldehyde in acetone (76).
New Zealand rabbits (n=2) were injected intramuscularly with 10 mg of rabbit
serum albumin (RSA) treated with 2 % glutaraldehyde in Freund's complete
adjuvant. At weeks 2, 3 and 4 the rabbits were given subcutaneous injections of 10
mg of antigen without adjuvant. Blood samples were taken at weeks 5, 6 and 7.
The sera from each rabbit were pooled and analyzed for elicited antibodies using
enzyme-linked immunosorbent assay (ELISA) and horseradish peroxidase assay. A
weak immunologic response was observed. The average IgG concentration in
response to glutaraldehyde treated RSA was 0.02 mg/ml serum (17).
11. Observations in man
11.1. Effects by contact and systemic distribution
Glutaraldehyde solutions may cause mild to severe irritation in the skin, depending
on the concentration of the solution and the duration of exposure/contact. Inhalation
of glutaraldehyde at vapour levels below 0.8 mg/m3 (0.2 ppm) has been reported to
cause nose and throat irritation, nausea and headaches (11). Chest discomfort and
tightness and breathing difficulty may also occur.
When glutaraldehyde treated drug-loaded erythrocytes were used in systemic
chemotherapy of a near-terminal male patient (97), no side-effects were observed
due to glutaraldehyde.
A very specific effect of glutaraldehyde has been described, where endoscopes,
sterilised by glutaraldehyde, have produced corrosive mucosal lesions in form of
necrotic hemorrhagic colitis. The effect in this case is on the patient not on the
occupationally working personnel and caused by direct contact with glutaraldehyde
(12, 27).
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11.2. Effects of repeated exposure on organ systems
From 65 % of 167 nurses working in endoscopy units there have been complaints
of eye irritation, skin irritation, headache and cough or shortness of breath. Where
measurements were performed the air concentration of glutaraldehyde was less than
0.2 ppm (13).
In an irritancy test (79), a 10 % solution of glutaraldehyde was applied to the
anterior, lateral, and posterior ankle and posterior heel of twelve subjects (3 black
and 9 white). The application was done 5 days/week for 4 weeks, and thereafter
3 days/week for further 4 weeks. No irritation (erythema, pruritus, or isolated
vesicles and papules) was observed during the first week. However, in 11 subjects
the skin was discoloured after 5 applications. During the second week, all subjects
were significantly discoloured, and 5 out of 12 had minimal irritation on the anterior
ankle. One of the five subjects became sensitised to glutaraldehyde. During the
remaining 6 weeks of the study, the application was only done to areas of thick
stratum corneum (medial, posterior, and lateral heel and posterior ankle). The
irritation of the anterior ankle subsided during the third and fourth weeks of the
study. During the last four weeks of application, there was no evidence of irritancy,
even among those who had previously experienced some irritation. The skin colour
returned to normal within two weeks of the final glutaraldehyde application (= 10
weeks after the first application).
There are several cases of dermatitis due to repeated or prolonged contact with
glutaraldehyde or glutaraldehyde-containing disinfectant agents. The symptoms are
marked dryness, redness, eczema, infiltrations, fissures and skin sensitisation (6,
11, 24, 26, 33, 35, 40, 43, 67, 93, 101).
In a study tests on 109 volunteers were conducted using 0.1 %, 0.2 % and 0.5 %
(w/w) aqueous solutions of glutaraldehyde with the same concentration being used
for induction and challenge. For induction the glutaraldehyde doses were applied to
the skin of the backs under occlusion for 48 to 72 hours. A total of ten induction
applications were made over a 3 week period. Two weeks after removal of the final
induction patch, a challenge patch was applied under occlusion for 48 hours to a site
not used for induction. The reaction was recorded 24 hours after removal of the
challenge patch. The two lowest doses produced no evidence for a sensitization
reaction, but at 0.5 % there was a definite reaction to the challenge patch in one of
the 109 subjects. While 0.1 % and 0.2 % glutaraldehyde were not significantly
irritating to the skin, 0.5 % produced mild to moderate local erythema in 16 of the
109 subjects (4).
Glutaraldehyde was tested for sensitization in 102 male subjects. Ten occlusive
induction patches containing 0.1 % glutaraldehyde in petrolatum were applied to the
upper lateral portion of the arm for 48 to 72 h over 3 weeks. A nontreatment period
of 2 weeks was followed by an occlusive challenge patch containing 0.5 % glutaral-
dehyde in petrolatum. Skin reactions were graded on a scale of 1 to 4 and a grade 2
or greater was considered positive. No sensitization was observed among the 102
men. The experiment was repeated with 30 men and with 5.0 % glutaraldehyde
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induction patches and a 0.5 % glutaraldehyde challenge patch. Seven (23.3 %) of
the men were sensitized (60).
In  studies at hospitals by NIOSH a relationship between exposure to
glutaraldehyde and irritation of eyes and upper respiratory pathways has been
demonstrated. The occupational concentration of glutaraldehyde was 0.2 ppm or
higher. After reconstruction of the occupational setting the concentration was
lowered to 0.1 ppm or less and there were no symptoms of irritation (68).
There is limited evidence from case reports that glutaraldehyde would cause
respiratory sensitisation (8, 11, 22, 49). However, two of four nurses, complaining
of respiratory symptoms, reacted positive in a provocation test when exposed to
glutaraldehyde vapour, as measured by changes in FEV1.0 and nasal airway
resistance (an index of nasal obstruction) (21). The respiratory symptoms included
sneezing, wheezing, chest tightness and breathing difficulties.
In an outpatient clinic in Nairobi glutaraldehyde for instrument decontamination
was left in an open vessel in a room of 11.4 m3, ventilated through 1.44 m2
windows, which remained open for about 10 h daily during a 5-day week. Five
persons (doctors and nurses) were working in that room. The symptoms reported
were itching and watery eyes, sneezing, headaches, nausea, coughing, breath-
lessness, acute rhinitis, bronchitis and nasal irritation. The authors (65) believe that
the adverse reactions to glutaraldehyde probably corresponded to development of
hypersensitivity to glutaraldehyde. Provocation tests were, however, not per-
formed.
There are also cases of occupational asthma due to exposure to glutaraldehyde
used as a sterilising agent. The diagnosis of occupational asthma was documented
by tests for preshift and postshift spirometry, serial measurements of peak expira-
tory flow rate and nonspecific bronchial hyperresponsiveness, and workplace
challenge (16, 39).
There is another case report on one endoscopy nurse who developed symptoms
suggestive of occupational asthma after seven years of exposure to glutaraldehyde.
The exposure had increased during the last 18 months. During that time, she deve-
loped symptoms of breathlessness, wheeze, chest tightness and cough. Chest
tightness and wheezing developed immediately on exposure to glutaraldehyde and
wore off after one or two hours. The asthmatic symptoms were accompanied by
hoarseness, sore eyes, sore throats and sneezing (88).
Occupational exposure to glutaraldehyde has been reported to cause palpitations
or tachycardia. The symptoms ceased when the exposure to glutaraldehyde ceased.
No exposure data were given (18).
11.3. Genotoxic effects
No studies on genotoxic effects of glutaraldehyde to man have been found in the
literature.
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11.4. Carcinogenic effects
In a mortality study of 186 workers exposed to glutaraldehyde (0.2 ppm) in a
glutaraldehyde-producing plant between 1959 and 1978, there was no increased
insidence of malignant tumours. Nor was there an increased mortality rate according
to an unpublished industrial study presented in the German MAK-committee (82).
This study has later been published (95). The mortality analysis included 186 males
assigned to glutaraldehyde production or drumming from 1959 to 1978, who were
followed through 1988. Traditional SMR adjusting for age and calendar year were
conducted using US mortality rates for white males through 1989 for calculation of
expected deaths. To control for healthy worker effect and unmeasured confounders,
internal comparisons using the men from the Kanawha Valley cohort never assigned
to the glutaraldehyde unit as a referent group were also conducted. There were 14
deaths among the 186 study subjects. There were 4 cancer deaths versus 6.1
expected. The four cancers included one each due to stomach, lung and brain and a
death due to lymphosarcoma.
11.5. Reproductive and developmental effects
The assessment of spontaneous abortions and foetal malformations have been
studied in Finnish hospital nurses and staff who had been exposed to glutaral-
dehyde used as a sterilising agent. No increase in risk of either endpoint was found
(45, 46, 71).
There is no information available on human reproductive toxicity.
12. Dose-effect and dose-response relationships
From animal inhalation studies the relationship between exposure dose and effect is
given in Table 2. LD50 values (oral) varies between 50 mg/kg bw in guinea pigs
and about 100 mg/kg bw in rats and mice. The TDLO in rats is given to 54.6 mg/kg
bw.
The dermal LD50 in rats and rabbits is approximately 2500 mg/kg bw.
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Table 2 Effects of inhalation exposure to glutaraldehyde in rats and mice.
Species Exposure Effect Ref
rat (n.s.) 24-120 ppm; 4 h LC50 5
mouse Swiss 2.6 ppm; 15 min RD50 107
rat F344 1.6 ppm; 6h/d;5d/w;2w no weight gain 71
mouse BCF 1.6 ppm; 6h/d;5d/w;2w 10/10 animals died 71
mouse BCF 1.0 ppm; 6h/d;5d/w;13w 20/20 animals died 71
rat, m F344 1.0 ppm; 6h/d;5d/w;13w reduced body weight gain 71
mouse Swiss 1.0 ppm; 14 days squamous metaplasia in the nose;
necrosis of respiratory epithelium
107
rat F344 0.5 ppm; 6h/d;5d/w;13w squamous metaplasia in the nose 71
rat, f F344 0.5 ppm; 6h/d;5d/w;13w reduced body weight gain 71
mouse Swiss 0.3 ppm; 4 days lesions in respiratory epithelium 107
mouse, f BCF 0.25 ppm; 6h/d;5d/w;13w reduced body weight gain 71
rat F344 0.25 ppm; 6h/d;5d/w;13w nasal inflammation 71
mouse, m BCF 0.125 ppm; 6h/d;5d/w;13w reduced body weight gain 71
rat F344 0.125 ppm; 6h/d;5d/w;13w NOAEL for respiratory lesions 71
mouse BCF 0.0625 ppm; 6h/d;5d/w;13w nasal inflammation 71
n.s. = strain not stated
13. Previous evaluations by (inter)national bodies
The German MAK-committee has evaluated glutaraldehyde in 1993 (82). The
MAK-value (0.1 ppm) is based on irritative effects in eyes, nose and respiratory
epithelium. Due to the irritative effects there is also a 5 min short-term value of
0.2 ppm. The teratogenic and embryotoxic risk is evaluated as none.
Glutaraldehyde is marked as a sensitiser (allergen).
In a revision 1992 of the documentations for the ACGIH TLVs, a ceiling value
(0.2 ppm) is recommended for glutaraldehyde vapour based on the irritation
threshold of glutaraldehyde (1).
14. Evaluation of human health risks
14.1 Groups at extra risk
Individuals sensitised to formaldehyde or glyoxal seem to have a greater risk for
reacting to glutaraldehyde. There seems to be a possibility for cross-reactions
between these aldehydes. Glutaraldehyde as such is, however, said to be a strong
human sensitiser.
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14.2 Assessment of health risks
Data from occupational exposure are scarce. Direct skin contact with glutaraldehyde
should be avoided. Also water solutions of glutaraldehyde can irritate and affect the
skin. There is also the risk of being sensitized.
Vapours of glutaraldehyde causes eye, nose and throat irritation, nausea and
headaches. The LOEL (lowest observed effect level) for the irritative effects is
below 0.2 ppm which is comparable to animal data. Glutaraldehyde vapours may
also cause asthma. Symptoms include sneezing, wheezing, chest tightness and
breathing difficulties.
From animal studies histopathological effects in the nose have been demonstrated
in rats and mice. The lesions included epithelial erosions, inflammation, and
squamous metaplasia in the anterior third of the nose. Lesions were of a similar
kind as caused by formaldehyde, although they were more anterior than those
reported for formaldehyde.
Glutaraldehyde is genotoxic in vitro and induces mutations in both bacterial and
mammalian cells. Glutaraldehyde also produces sister chromatid exchanges and
chromosomal aberrations in mammalian cells in vitro. However, an in vivo
micronucleus test in mice and a bone marrow chromosomal aberration test in rats
yielded negative results.
The results from an ongoing carcinogenesis study has not yet been reported.
14.3. Scientific basis for an occupational exposure limit
There are very few data which can be used as a scientific basis for an occupational
exposure limit for glutaraldehyde. The critical effect, based on these data, is
irritation of the skin, the eyes and the mucous membranes. The LOEL for irritative
effects is below 0,2 ppm. However, from data on mice, 13 weeks inhalation of
0.0625 ppm (lowest tested) glutaraldehyde caused nasal inflamation  Moreover,
glutaraldehyde is a skin allergen and may cause respiratory allergic reactions.
15. Research needs
No long-term (more than 13 weeks) inhalation studies have been performed in
animals  and there is a lack of epidemiological data from exposure to glutaral-
dehyde. The local effect in the nasal mucosa should be compared to the effects of
e.g. formaldehyde, thereby also investigating the toxicological mechanisms
involved.
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16. Summary
Beije B, Lundberg P. Glutaraldehyde. DECOS and NEG Basis for an Occupational
Standard. Arbete och Hälsa 1997;20, pp 1-30.
Glutaraldehyde is used, among other things, as a fixative in electron microscopy, a
disinfectant for instruments and in chemical industry. It is a skin and mucous
membrane irritant. Glutaraldehyde is a skin allergen and may cause respiratory
allergic reactions. In rats and mice histopathological effects in the nose have been
demonstrated. Glutaraldehyde is genotoxic in vitro and induces mutations in both
bacterial and mammalian cells. It also produces sister chromatid exchanges and
chromosomal aberrations in mammalian cells in vitro. Based on relatively few
available data the critical effect when occupationally exposed is irritation of the skin,
the eyes and the mucous membranes.
Keywords : Human toxicity, irritation, metabolism, mutagenicity, occupational
exposure, occupational exposure limit, risk evaluation, sensitization
17. Summary in Swedish
Beije B, Lundberg P. Glutaraldehyde. DECOS and NEG Basis for an Occupational
Standard. Arbete och Hälsa 1997;20, s 1-30.
Glutaraldehyd används bl a som fixativ i elektronmikroskopi, som
desinfektionsmedel för instrument och i kemisk industri. Ämnet irriterar hud och
slemhinnor. Glutaraldehyd är en hudallergen och kan ge allergiska reaktioner i
andningsvägarna. Hos råtta och mus har histopatologiska effekter i nosen påvisats.
Glutaraldehyd är genotoxisk in vitro och inducerar mutationer i såväl bakterier som
mammalieceller. Det ger även systerkromatidutbyten och kromosomaberrationer i
mammalieceller in vitro. Baserat på relativt få tillgängliga data är den kritiska
effekten vid yrkesmässig exponering irritation av hud, ögon och slemhinnor.
Nyckelord : Humantoxicitet, hygieniskt gränsvärde, irritation, metabolism,
mutagenicitet, riskvärdering, sensibilisering, yrkeshygienisk exponering
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19. Data bases used in search for literature
In the search for literature the following data bases were used:
- NIOSHTIC
- Cancerline
- Chemical Abstracts
- Medline
- Toxline
- RTECS
The latest search was performed February 17, 1997, at the library of the Swedish
National Institute for Working Life. In order not to miss any references the only
search-words used were "111-30-8" (the CAS nr) and "glutaraldehyde".
Submitted for publication, October 6, 1997.
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Appendix 1.
Permitted or recommended maximum levels of glutaraldehyde in air.
Land ppm mg/m3 Kommentarer År Ref.
Denmark 0.2 0.8 Ceiling 1994 1
Finland 0.1 0.42 Short term 1996 2
Germany 0.1 0.4 S 1996 7
0.2 0.8 5 min short term
Iceland 0.2 0.8 Ceiling 1989 3
Netherlands - 0.25 Ceiling 1996 4
Norway 0.2 0.8 Ceiling 1995 5
- 0.25 Activated glutaraldehyde
Sweden 0.2 0.8 Ceiling; S 1996 6
USA (ACGIH) 0.2 0.82 Ceiling 1996 8
0.05 0.2 intended change
(NIOSH) 0.2 0.8 Takvärde 1994 9
(OSHA) - - 1994 9
S = risk for sensitisation
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